Immunovant Inc

Immunovant Inc(IMVT)資訊與事件

$41.200

-2.464 (-5.98%)收盤時

IMVT 資訊

IMVT 事件

8/6 08:00

Immunovant on Track with IMVT-1402 Development Plans

The company said, "Immunovant's development plans for IMVT-1402 remain on track across all six announced indications. The Company expects to provide further updates on its potentially registrational IMVT-1402 D2T RA program and report topline data from the proof-of-concept trial of IMVT-1402 in CLE in the second half of calendar year 2026. In calendar year 2027, topline data are anticipated for the potentially registrational trials evaluating IMVT-1402 in GD and MG. Topline data are expected to follow in calendar year 2028 for the potentially registrational trials of IMVT-1402 in CIDP and SjD."

5/20 12:10

Immunovant Stock Rises 33.6% to $35.12

Immunovant is up 33.6%, or $8.83 to $35.12.

5/20 10:10

Immunovant Stock Rises 25.9% to $33.09

Immunovant is up 25.9%, or $6.80 to $33.09.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始